Advertisement
Singapore markets close in 1 hour 53 minutes

  • Straits Times Index

    3,138.24
    -45.37 (-1.43%)
     

  • Nikkei

    38,471.20
    -761.60 (-1.94%)
     

  • Hang Seng

    16,228.74
    -371.72 (-2.24%)
     

  • FTSE 100

    7,965.53
    0.00 (0.00%)
     

  • Bitcoin USD

    63,266.21
    -3,092.08 (-4.66%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     

  • Dow

    37,735.11
    -248.13 (-0.65%)
     

  • Nasdaq

    15,885.02
    -290.08 (-1.79%)
     

  • Gold

    2,388.70
    +5.70 (+0.24%)
     

  • Crude Oil

    85.63
    +0.22 (+0.26%)
     

  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,536.48
    -6.05 (-0.39%)
     

  • Jakarta Composite Index

    7,180.01
    -106.87 (-1.47%)
     

  • PSE Index

    6,404.97
    -157.46 (-2.40%)
     

Here's Why Innate Pharma Stock Is Rocketing Higher Today

Cory Renauer, The Motley Fool
·2-min read
Here's Why Innate Pharma Stock Is Rocketing Higher Today

Shares of Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company, are rocketing higher in response to successful clinical-trial data for an experimental cancer drug called monalizumab. Monalizumab is currently in a phase 2 trial called Coast, in combination with Imfinzi from AstraZeneca (NASDAQ: AZN). Imfinzi is approved to treat advanced-stage non-small cell lung cancer (NSCLC) patients with tumors that haven't grown since beginning standard first-line treatment.

Continue reading